01
What changed in pharmaceuticals regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
The GDUFA IV agreement, finalized in September 2026, introduces new regulatory provisions for generic drug manufacturers.
Read at citeline.com ↗03
The U.S. government is expanding a 100% tariff on patented pharmaceutical products and active ingredients to additional drugmakers starting September 29, 2026.
Read at inboundlogistics.com ↗04
During a Senate HELP Committee confirmation hearing on September 24, 2026, FDA commissioner nominee Heidi Overton affirmed that vaccines and mifepristone are safe and effective.
Read at fiercehealthcare.com ↗05
Senator Todd Young, chairman of the National Security Commission on Emerging Biotechnology, is advocating for a stronger U.S. biotech innovation ecosystem to counter China's growing influence in the sector.
Read at fiercebiotech.com ↗06
The chairs of nine major European pharmaceutical companies, including AstraZeneca, GSK, and Novo Nordisk, sent a letter to European national leaders on September 22, 2026, warning that Europe is losing competitiveness to the US and China in drug development and investment.
Read at theguardian.com ↗07
The U.S. government has finalized 'most-favored-nation' drug pricing agreements with 26 pharmaceutical companies as of September 2026.
Read at biopharmadive.com ↗08
The Trump administration announced on September 18, 2026, that all 50 U.S. states, the District of Columbia, and Puerto Rico have applied to participate in the GENEROUS Medicaid drug pricing model.
Read at fiercehealthcare.com ↗8 of 22 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in pharmaceuticals this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
Eli Lilly and mid-sized pharmaceutical companies are leading the M&A activity in the healthcare sector throughout 2026.
Read at citeline.com ↗10
Enveda, a biotech startup based in the United States, has raised $311 million in a Series E funding round led by Catalio Capital Management.
Read at techcrunch.com ↗11
London-based Basecamp Research has raised $140 million in a Series C funding round led by S32.
Read at sifted.eu ↗12
On September 23, 2026, the biotechnology company Enveda Biosciences announced it is expanding its efforts to discover new drugs by utilizing artificial intelligence to analyze natural compounds.
Read at citeline.com ↗13
AbbVie has entered a multi-year partnership with Iambic to utilize AI models for drug discovery in immunology, neuroscience, and oncology.
Read at pharmexec.com ↗14
Telix Pharmaceuticals has entered into a definitive agreement to acquire ITM Isotope Technologies Munich for $1.65 billion in an upfront payment.
Read at fiercebiotech.com ↗15
Eli Lilly and Co. broke ground on a $6.5 billion manufacturing facility in Houston, Texas, on Monday, September 21, 2026.
Read at bisnow.com ↗16
The National Cancer Institute (NCI) introduced the Strategic Breakthrough Program, offering up to $30 million in funding for innovations targeting pediatric and rare cancers.
Read at bio.news ↗8 of 14 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in pharmaceuticals this week?
Notable product launches, releases and platform updates from the week.
17
Seattle-based biotech company Talus Bio has developed a new drug discovery model called Ptarmigan-1 that bypasses protein folding predictions.
Read at drugdiscoverytrends.com ↗18
The Global Climate and Health Alliance (GCHA) has launched a new resource titled 'Fossil PR Toolkit' on September 25, 2026.
Read at citeline.com ↗19
Alexion Pharmaceuticals is planning to enter the generalized myasthenia gravis (gMG) treatment market with its drug candidate gefurulimab.
Read at citeline.com ↗20
Oracle announced the expansion of its Life Sciences Data Intelligence platform at the Oracle Health and Life Sciences Summit 2026 in Orlando, Florida, on September 23, 2026.
Read at fiercehealthcare.com ↗21
Novo Nordisk executives held a capital markets day in London on September 23, 2026.
Read at pharmavoice.com ↗22
Johnson & Johnson is pursuing a $5 billion annual sales target for the psychiatric drug Caplyta, supported by new clinical data regarding its efficacy in treating bipolar mania.
Read at citeline.com ↗23
Körber has launched K.AI Assistant, a generative AI tool specifically designed for GxP-regulated pharmaceutical and life sciences manufacturing environments.
Read at logisticsviewpoints.com ↗24
Walmart is launching a six-month pilot program starting September 15, 2026, in five rural U.S. stores.
Read at thestreet.com ↗8 of 9 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in pharmaceuticals this week?
Earnings, guidance and other financial results reported this week.
25
Iambic Therapeutics is preparing for an initial public offering (IPO) following a recent funding round and several partnerships with major pharmaceutical companies.
Read at fiercebiotech.com ↗26
Biotech companies TRex Bio, which is backed by Eli Lilly, and Retension Pharmaceuticals have announced their intentions to launch initial public offerings in 2026.
Read at fiercebiotech.com ↗27
Novo CEO Mike Doustdar addressed investor concerns during the company's Capital Markets Day on September 21, 2026.
Read at fiercebiotech.com ↗What court rulings and legal actions hit pharmaceuticals this week?
Court rulings, filings and legal actions reported this week.
28
A jury in the Northern District of California awarded Nektar Therapeutics $90 million in damages after finding that Eli Lilly breached a covenant of good faith in their collaboration agreement for the drug candidate rezpegaldesleukin.
Read at genengnews.com ↗29
The Supreme Court's 2020 Rutledge v. Pharmaceutical Care Management Association decision established that ERISA does not automatically preempt state regulation of pharmacy benefit manager (PBM) reimbursement rates.
Read at pharmexec.com ↗30
A federal court in Minnesota issued a consent decree banning Gold Star Distribution Inc. and its owner, Bassam Abu Samrah, from operating in the food, drug, and medical device industries.
Read at foodsafetynews.com ↗31
Johnson & Johnson secured a patent victory for its depression drug Spravato, which uses esketamine.
Read at pharmavoice.com ↗32
Florida Attorney General James Uthmeier filed a lawsuit in the state's 11th Judicial Circuit Court during the week of September 23, 2026, against three major insulin manufacturers and three pharmacy benefit managers (PBMs).
Read at fiercehealthcare.com ↗33
A group of consumers appeared before a Seventh Circuit panel in Chicago on September 23, 2026, to appeal the dismissal of a class-action lawsuit against AbbVie.
Read at courthousenews.com ↗34
Eli Lilly and Company is engaged in a legal and regulatory dispute with the US Food and Drug Administration regarding the classification of its obesity drug, Retatrutide.
Read at citeline.com ↗35
The Alberta Court of King's Bench has approved the distribution of a $7.5-million settlement in a class action lawsuit against GlaxoSmithKline regarding birth defects linked to the antidepressant Paxil.
Read at canadianlawyermag.com ↗8 of 9 courts and legal events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What research was published in pharmaceuticals this week?
New research findings and studies published this week.
36
A new survey of 100 US healthcare providers reveals that fewer than 3% of sickle cell disease patients receive red blood cell exchange therapy, despite 91% of providers having access to the technology.
Read at theguardian.com ↗37
Researchers led by Jian Li at Harvard Medical School identified that silencing the ALDH3B2 gene in human pancreatic ductal cells increases their conversion into insulin-producing beta-like cells from less than 1 percent to approximately 8.5 percent.
Read at wired.com ↗38
AbbVie is developing a trispecific antibody, ABBV-2001, targeting multiple myeloma.
Read at citeline.com ↗39
Anthropic announced that its AI model Claude autonomously discovered a previously uncharacterized enzyme system in bacteriophages.
Read at theverge.com ↗40
Roche has announced positive phase 3 clinical trial results for its drug candidate sefaxersen, which is being developed in partnership with Ionis Pharmaceuticals for the treatment of kidney disease.
Read at fiercebiotech.com ↗41
Anthropic CEO Dario Amodei predicted on Wednesday, September 23, 2026, that artificial intelligence could help cure most major diseases within the next five to ten years.
Read at foxbusiness.com ↗42
Roche has announced positive results from a phase 2 clinical trial of its dual GLP-1/GIP receptor agonist.
Read at fiercebiotech.com ↗43
Viking Therapeutics reported trial data on September 22, 2026, showing that its experimental obesity drug VK2735 achieved 21.7% weight loss at 33 weeks without plateauing.
Read at thestreet.com ↗8 of 40 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit pharmaceuticals this week?
Incidents, outages and safety events reported this week.
44
Xenon Pharmaceuticals shares fell 30% on September 18, 2026, following a temporary pause in new patient enrollment for its depression trials of the drug azetukalner due to adverse neuropsychiatric events.
Read at thestreet.com ↗What partnerships were announced in pharmaceuticals this week?
Partnerships, integrations and joint projects announced this week.
45
Thar Process, a Pittsburgh-based supercritical fluid technology company, has partnered with the French firm ExtrateX to distribute its Isolator SFC systems across Europe.
Read at genengnews.com ↗1 of 8 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.